Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies ...

The option has an exercise price equal to the closing price of Autonomix's common stock as reported by the Nasdaq Capital ...

Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104 ...

Robot Corp. (NASDAQ: IRBT), a leader in consumer robots, today announced that it granted an equity award as a material inducement to the employment of the company's newly-hired Senior Vice President ...

European Wax Center, Inc. (NASDAQ: EWCZ) (the "Company” or "European Wax Center”), the leading franchisor and operator of out ...

The performance stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a performance stock unit agreement covering the grant. The 2024 ...

The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of March 16, 2025 ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment ...

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating ...